Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction-Reference-Cited by-同舟云学术

Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction

Published:2021-05-01 Issue:5 Volume:6 Page:499
ISSN:2380-6583
Container-title:JAMA Cardiology
language:en
Short-container-title:JAMA Cardiol

Author:

Berg David D.¹,Jhund Pardeep S.²,Docherty Kieran F.²,Murphy Sabina A.¹,Verma Subodh³,Inzucchi Silvio E.⁴,Køber Lars⁵,Kosiborod Mikhail N.⁶,Langkilde Anna Maria⁷,Martinez Felipe A.⁸,Bengtsson Olof⁷,Ponikowski Piotr⁹,Sjöstrand Mikaela⁷,Solomon Scott D.¹⁰,McMurray John J. V.²,Sabatine Marc S.¹

Affiliation:

1. TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women’s Hospital, Boston, Massachusetts

2. BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom

3. Division of Cardiac Surgery, St Michael's Hospital, University of Toronto, Toronto, Canada

4. Section of Endocrinology, Yale School of Medicine, New Haven, Connecticut

5. Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark

6. Saint Luke's Mid America Heart Institute, University of Missouri, Kansas City, Missouri

7. Late Stage Development, Cardiovascular, Renal and Metabolism BioPharmaceuticals Research and Development, AstraZeneca, Gothenburg, Sweden

8. Universidad Nacional de Córdoba, Córdoba, Argentina

9. Center for Heart Diseases, University Hospital, Wrocław Medical University, Poland

10. Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, Massachusetts

Publisher

American Medical Association (AMA)

Subject

Cardiology and Cardiovascular Medicine

Link

https://jamanetwork.com/journals/jamacardiology/articlepdf/2776351/jamacardiology_berg_2021_oi_200098_1620406042.35091.pdf

Reference12 articles.

1. Dapagliflozin in patients with heart failure and reduced ejection fraction.;McMurray;N Engl J Med,2019

2. Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF Registry.;Greene;J Am Coll Cardiol,2018

3. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure.;Solomon;Circulation,2007

4. Influence of previous heart failure hospitalization on cardiovascular events in patients with reduced and preserved ejection fraction.;Bello;Circ Heart Fail,2014

5. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America.;Yancy;Circulation,2017

Cited by 120 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Performance of sodium-glucose cotransporter 2 inhibitors in cardiovascular disease;Journal of Cardiovascular Medicine;2024-02-01

2. Chapter 3: Clinical Trials of Sodium-Glucose Co-Transporter-2 Inhibitors for Treatment of Heart Failure;The American Journal of Medicine;2024-02

3. Medicines optimization prior to discharge in patients admitted to hospital with heart failure;ESC Heart Failure;2024-01-16

4. Comparative analysis of SGLT2 inhibitors in the treatment of heart failure;InterConf;2023-12-20

5. Risk of readmission and death after hospitalization for worsening heart failure: Role of post‐discharge follow‐up visits in a real‐world study from the Grand Est Region of France;European Journal of Heart Failure;2023-12-18